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Mycobacterium tuberculosis infection remains a
major global health problem complicated by esca-
lating rates of antibiotic resistance. Despite the
established role ofmycolic acid cyclopropanemodifi-
cation in pathogenesis, the feasibility of targeting this
enzyme family for antibioticdevelopment is unknown.
We show through genetics and chemical biology
that mycolic acid methyltransferases are essential
for M. tuberculosis viability, cell wall structure, and
intrinsic resistance to antibiotics. The tool compound
dioctylamine, which we show acts as a substrate
mimic, directly inhibits the function of multiple
mycolic acid methyltransferases, resulting in loss of
cyclopropanation, cell death, loss of acid fastness,
and synergistic killing with isoniazid and ciprofloxa-
cin. These results demonstrate that mycolic acid
methyltransferases are a promising antibiotic target
and that a family of virulence factors can be chemi-
cally inhibited with effects not anticipated from
studies of each individual enzyme.
INTRODUCTION
Human infection with Mycobacterium tuberculosis continues to
cause unrelenting suffering. Although infection with M. tubercu-
losis is a curable with prolonged multidrug antibiotic therapy,
the drug regimens are often toxic or difficult to complete. In the
developing world, curative therapy forM. tuberculosis is difficult
to execute, leading to twomillion deathsper yearworldwide (Dye,
2006). Infection with antibiotic-resistant M. tuberculosis is an
increasing problem and requires more prolonged antibiotic
therapy for cure (World Health Organization, 2008). In the case
of extensively drug-resistant tuberculosis, therapy is often
impossible (Gandhi et al., 2006). This dire reality has prompted
a significant worldwide effort to discover new drugs to treat
M. tuberculosis infection. Although any new agent active against
M. tuberculosiswould be welcome, of particular interest are new
drugs that would allow shortening of tuberculosis chemotherapy
through rational targeting of gene products important for persis-Chemistry & Biology 16tent infection. An increasing number of potential drug targets in
M. tuberculosis are cell wall biosynthetic enzymes, including
enzymes involved in mycolic acid biosynthesis andmodification.
Mycolic acids are a-alkyl, b-hydroxy fatty acids that are
produced by all mycobacteria and are the signature lipid of the
hydrophobic mycobacterial cell wall. Mycolic acid biosynthesis
has been intensely studied due to the unique structure of these
lipids and their importance for tuberculosis antibiotic therapy
andM. tuberculosispathogenesis (Barry et al., 1998).M. tubercu-
losis andMycobacteriumbovis produce threemajormycolic acid
types: alpha mycolate, methoxymycolate, and ketomycolate.
The chemical structures of these lipids shown in Figure 1 were
determined over years of exhaustive study (Barry et al., 1998;
Watanabe et al., 2002, 2001). Although the core mycolate
structure is conserved among mycobacteria, only pathogenic
slow growing mycobacteria produce significant amounts of
cyclopropanated mycolic acids. Alpha mycolic acids contain
two cis cyclopropane rings on the meromycolate chain. Oxygen-
ated mycolates contain either a distal methoxy or ketone group
and a proximal cis or trans cyclopropane ring. The cyclopropane
rings and methyl branches of these lipids are synthesized by
a family of S-adenosyl methionine-dependent methyltrans-
ferases. The enzymes of this family are highly homologous both
in primary sequence and tertiary structure (Huang et al., 2002).
Despite this structural similarity, genetic deletion of eachmethyl-
transferase in M. tuberculosis has revealed highly specific
biosynthetic roles of each enzyme. PcaA and MmaA2 are
required for alpha mycolate cyclopropanation (Glickman, 2003;
Glickman et al., 2000), CmaA2 for trans cyclopropanation of the
oxygenated mycolates (Glickman et al., 2001), MmaA4 and
MmaA3 for distal functionality of the oxygenated mycolates
(Behr et al., 2000; Dubnau et al., 2000), and MmaA1 for methyl
branch formation preceding the cyclopropanation step by
CmaA2 (M.S.G., unpublished data).
M. tuberculosis strains deficient for cyclopropanation have
revealed an important role for this lipid modification in pathogen-
esis. Loss of pcaA in M. tuberculosis causes an early growth
defect in the lungs, defective persistence during late infection,
and failure to activate macrophage innate immune responses
(Glickman et al., 2000; Rao et al., 2005). In contrast, loss of
cmaA2 results in hypervirulence and hyperinflammatory innate
immune activation in macrophages (Rao et al., 2006) and loss
ofmmaA4 causes excessive IL-12 production (Dao et al., 2008)., 499–509, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 499
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of cyclopropane-deficient trehalose dimycolate, implicating
cyclopropanation as an immunomodulatory lipid modification
(Dao et al., 2008; Rao et al., 2005, 2006). However, these results
do not clearly define mycolic acid methyltransferases as an
attractive drug target in M. tuberculosis because the conse-
quences of complete cyclopropane loss are unknown and target-
ing of CmaA2 alone in preference to other methyltransferases
might be deleterious to the host.
In this study we address the suitability of mycolic acid methyl-
transferases as anM. tuberculosis drug target. We show that the
mycolic acid methyltransferase enzyme family can be targeted
by a single tool compound and that this inhibition has pleiotropic
effects on M. tuberculosis cells, including loss of cell wall integ-
rity and eventual cell death.
Figure 1. Chemical Structures of the Major Mycolic Acids of
M. tuberculosis and BCG-R
Cyclopropane rings and methyl branches are shown and annotated with the
methyltransferase responsible for their synthesis. BCG-P lacks methoxymy-
colates due to a mutation in MmaA3.500 Chemistry & Biology 16, 499–509, May 29, 2009 ª2009 ElsevieRESULTS
Deletion of cmaA2 from BCG Pasteur Is Only Possible
after Complementation with a FunctionalmmaA3
Previous work from our laboratory and others has shown that
mycolic acid methyltransferases are individually nonessential
for growth in vitro (Behr et al., 2000; Dubnau et al., 2000, 1998;
Glickman, 2003; Glickman et al., 2001, 2000), including the trans
cyclopropane synthase of the oxygenated mycolates CmaA2
(Glickman et al., 2001). As we have shown that deletion of cmaA2
from M. tuberculosis produces a hypervirulent strain (Rao et al.,
2006), we attempted to delete this gene from BCG Pasteur
(BCG-P) to study its effect on BCG immunogenicity. To delete
cmaA2, we infectedBCG-Pwith a temperature-sensitive special-
ized transducing phage designed to replace the entire cmaA2
coding sequence with a hygromycin resistance gene. To our
surprise, despite our prior deletion of cmaA2 fromM. tuberculosis
using the same technique, wewere unable to obtain hygromycin-
resistant transductants on multiple attempts (data not shown).
We have successfully deleted multiple genes from BCG-P using
specialized transduction (data not shown; Glickman et al., 2000;
Makinoshima and Glickman, 2005), indicating that our failure to
obtain a cmaA2 knockout was not due to a general failure of
this technique in this strain. BCG-P, along with many other BCG
substrains, lacks methoxymycolates due to a point mutation in
mmaA3, the gene encoding the methyltransferase that adds the
methoxy group to methoxymycolates (Behr et al., 2000). BCG
Russia (BCG-R) has a functional MmaA3 and therefore synthe-
sizes methoxymycolates. We were able to delete cmaA2 from
BCG-R using the same specialized transducing phage that failed
in BCG-P (Figure 2A), indicating that lack of methoxymycolates
may be the factor preventing cmaA2 deletion in BCG-P. To test
this idea, we complemented BCG-P at the chromosomal attB
site with the mmaA3 gene (BCG-P attB::mmaA3). As previouslyFigure 2. Genetic Analysis of Mycolic Acid
Methyltransferase Synthetic Phenotypes
(A) Southern blot showing the deletion of cmaA2
from BCG-R. Genomic DNA was cut with EcoRI
and probed with a DNA fragment flanking cmaA2.
The predicted size for wild-type is 3.8 kb and for
DcmaA2 is 1.8 kb.
(B) Radio TLC from BCG-P and BCG-P attB::
mmaA3, showing the appearance of methoxymy-
colates in thecomplementedstrain.a, alphamyco-
lates; m, methoxymycolates; k, ketomycolates.
(C) Southern blot showing deletion of cmaA2 from
BCG-P attB::mmaA3. Fragment sizes are as in (A).
(D) BCG-Pwas complemented at the attB site with
mmaA3 gene under an AHT-sensitive promoter
and mycolic acids were analyzed from strains
grown with (+AHT) and without (AHT) inducer.
After the deletion of cmaA2 or mmaA1 from this
strain (while supplementing with AHT), AHT was
withdrawn and mycolic acids were prepared.
(E) Radio TLC showing the removal of mmaA3 by
zeocin marker exchange (see text for details).
Mycolates from parent strains and zeocin-resis-
tant transformants were analyzed by TLC.
(F) Growth curve (represented as OD600 measure-
ments) at 32.5C of BCG-P (A), BCG-P DcmaA2
(MGM1919; -), BCG-R (:), and BCG-R DcmaA2
(MGM295; ;).r Ltd All rights reserved
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1998), BCG-P attB::mmaA3 synthesized methoxymycolates
(Figure 2B). Transduction of BCG-P attB::mmaA3 with the
cmaA2 knockout phage resulted in successful deletion of cmaA2
(Figure 2C). To confirm that the function of cmaA2 in BCG is to
synthesize trans cyclopropane rings, as previously shown in
M. tuberculosis (Glickman et al., 2001), we isolated total mycolic
acids from the BCG attB::mmaA3 cmaA2::hyg strain and
analyzed them by nuclear magnetic resonance (NMR). Trans
cyclopropane ringswere not detected in theDcmaA2 strain, con-
firming that the function of CmaA2 is identical in BCG and
M. tuberculosis (see Figure S1A available online). This data sug-
gested that null mutations inmmaA3 and cmaA2may be synthet-
ically lethal for slow growing mycobacteria.
To further confirm synthetic lethality, we created an mmaA3
depletion strain that expressed mmaA3 from a tetracycline-
inducible promoter. This strain displayed anhydrotetracycline
(AHT)-dependent synthesis of methoxymycolates (Figure 2D,
left). Using specialized transduction, cmaA2 and mmaA1 were
deleted from this strain in the presence of AHT. Southern
blotting confirmed successful deletion of cmaA2 and mmaA1
(data not shown) and NMR of total mycolic acids from these
strains confirmed lack of trans cyclopropane rings (Figures
S1B–S1C) To our surprise, depletion of mmaA3 by AHT with-
drawal did not result in cell death (data not shown). Examination
of these strains revealed minimal methoxymycolate production
without AHT (Figure 2D, right), ruling out constitutive expression
of mmaA3 due to a mutation in the tetracycline repressor. This
result could indicate that mmaA3/mmaA1 and mmaA3/cmaA2
are not synthetically lethal. However, the tetracycline regulation
is somewhat leaky, which could allow survival due to the low
level methoxymycolate production that is visible in Figure 2D.
To completely remove the mmaA3 cassette from the DmmaA1
and DcmaA2 strains, we used marker exchange (Pashley and
Parish, 2003). A zeocin marked vector replaced the mmaA3
cassette after transformation and the resulting zeocin-resistant
transformants lacked methoxymycolates (Figure 2E), indicating
that sequential deletion of cmaA2/mmaA3 or mmaA1/mmaA3
is possible. Taken together, one interpretation of these genetic
studies is that compensatory changes in membrane fluidity in
the tetracycline depletion and zeocin strains allowed isolation
of the double mutants, possibly due to the order in which the
genes were deleted. To test whether the cmaA2/mmaA3 double
mutants have alterations inmembrane fluidity that would support
this model, we grew these strains in low temperature. We found
that deletion of cmaA2 from BCG-Rmoderately impaired growth
at 32 (Figure 2F). Strikingly, BCG-P grew poorly at 32 and inac-
tivation of cmaA2 in BCG-P abolished growth (Figure 2F). These
findings support the genetic data indicating that loss of cmaA2/
mmaA3 impairs viability due to alteration in membrane fluidity.
Dioctylamine Inhibits Multiple Pathways of Mycolic Acid
Modification
To investigate the phenotypic consequences caused by loss of
mycolicacidmodification,wesought achemical inhibitor of these
enzymes. Dioctylamine was recently identified as an inhibitor of
Escherichia coli CFAS, an enzyme that cyclopropanates the
membrane fatty acids of E. coli (Grogan and Cronan, 1997;
Guianvarc’h et al., 2006). The IC50 of dioctylamine for CFASChemistry & Biology 16was 4 mM. Dioctylamine is chemically similar to didecyldimethy-
lammoniumbromide (DDDMAB), which we have previously crys-
tallized in the active site of CmaA2 (Huang et al., 2002) (see
Figure 3A for structures), suggesting that dioctylamine might
also inhibit mycolic acid methyltransferases by acting as
a substrate mimic. To test whether dioctylamine is an inhibitor
of cyclopropanation, we grew BCG-R (which has a mycolic acid
Figure 3. Dioctylamine Inhibits Multiple Pathways of Mycolic Acid
Modification
(A) Chemical structures of dioctylamine and DDDMAB. DDDMAB was previ-
ously identified in the active site of crystals of CmaA2.
(B) One-dimensional TLC of mycolates isolated from BCG-R treated with the
concentration of dioctylamine (mM) indicated under each lane. Alpha mycolate
(a), methoxymycolate (m), and ketomycolate (k) are indicated at the left edge.
The arrowhead marks the position of methoxymycolate, which is absent from
the 2 mM sample. The arrow marks hydroxymycolate.
(C) Two-dimensional Argentation TLC of BCG-R treated with 0.5 mM dioctyl-
amine. The sample was separated without silver (dimension 1) and then with
silver (dimension 2). The silver dimension retards lipids on the basis of unsatu-
ration. Two unsaturated derivatives of alpha mycolate are visible, as well as
unsaturated ketomycolates and methoxymycolates (arrowhead).
(D and E) Two-dimensional Argentation TLC of BCG-R treated with 2 mM (D)
and 10 mM (E) dioctylamine. Unsaturated derivatives of the alpha mycolates
and ketomycolates are marked with arrowheads, as are the positions of
mature alpha mycolate (a), ketomycolate (k), and hydroxymycolate (hy)., 499–509, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 501
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and in escalating concentrations of dioctylamine ranging from
0.125 to 10 mM or vehicle control. After 6 hr, 14C-labeled mycolic
acidmethyl esterswereprepared andanalyzedby radio thin layer
chromatography (TLC). We observed that 2 mM dioctylamine
completely inhibited methoxymycolate production, consistent
with loss of MmaA3 function (see arrowhead in Figure 3B). In
addition, treatment with 4 and 10 mMdioctylamine caused accu-
mulation of a mycolic acid migrating slower than ketomycolate
(see arrow in Figure 3B), consistent with the previously reported
hydroxymycolate that accumulates in the absence of functional
MmaA3 (Quemard et al., 1997). This polar lipid migrated slower
than authentic epoxymycolate from Mycobacterium smegmatis
(data not shown), confirming its likely identity as hydroxymyco-
late. At 10 mM, there is substantial but incomplete inhibition of
ketomycolate biosynthesis (compare 0.125 to 10 mM in Fig-
ure 3B). The observed mycolic acid profiles with dioctylamine
treatment are consistent with loss of MmaA3 and MmaA4 func-
tion, suggesting that dioctylamine inhibits these enzymes.
Whereas inhibition of MmaA3 and MmaA4 leads to loss of
an entire mycolate class and is therefore easily detected on
one-dimensional TLC, chemical inhibition of other cyclopropane
synthasesproducesunsaturated lipids that are identical inpolarity
to their parent lipids and therefore not detectable on one-dimen-
sional TLC. This phenotype was previously demonstrated in
M. tuberculosis strains lacking the mycolic acid cyclopropane
synthasesPcaA,MmaA2, andCmaA2 (Glickman, 2003;Glickman
et al., 2001, 2000). To test the inhibition of these enzymes by dio-
ctylamine, we performed two-dimensional argentation TLC on
mycolic acids isolated from dioctylamine-treated BCG-R. In this
technique, lipids are first separatedbypolarity and thenbydegree
of any type of unsaturation in the second (silver) dimension. After
treatment of BCG-R with 0.5 mM dioctylamine, we observed two
unsaturated derivatives of the alpha mycolate, consistent with
inhibition of alpha mycolate cyclopropanation (Figure 3C, arrow-
head to the left of mature alpha). We also observed unsaturated
derivatives of methoxymycolates and ketomycolates, consistent
with impaired cyclopropanation of the proximal position of these
lipids (Figure 3C). Cells treated with 2 mM dioctylamine produced
no mature alpha mycolate and two species of unsaturated alpha
mycolate, the more abundant of which was more fully retarded
(arrowheads in Figure 3D). The ketomycolate appeared as three
species, mature keto and two unsaturated species, likely cis
and trans unsaturated. At 10 mM, almost no mature ketomycolate
was observed (Figure 3E). These data strongly indicate that dio-
ctylamine is a dose-dependent inhibitor of multiple mycolic acid
methyltransferases. These TLC data, combined with extensive
prior genetic characterization of mycolic acid modifications, indi-
cate that dioctylamine inhibits the lipid modifications performed
by MmaA4, MmaA3, PcaA, MmaA2, and CmaA2.
Mycolic Acid Methyltransferases Are Direct Targets
of Dioctylamine
The data presented above strongly indicate that dioctylamine
inhibits multiple pathways of mycolic acid cyclopropanation and
methylation. However, this effect could be due to direct inhibition
of mycolic acid methyltransferase enzymes or an indirect effect.
To prove that the methyltrasferases are direct dioctylamine
targets, we overexpressed hemagglutinin-tagged versions of502 Chemistry & Biology 16, 499–509, May 29, 2009 ª2009 ElsevierMmaA1,MmaA3,CmaA2, PcaA,MmaA2, andMmaA4on amulti-
copy episomal plasmid and tested the effect on dioctylamine
sensitivity. The expression of these proteins was confirmed by
western blotting in M. smegmatis and BCG-R (Figure S2). Over-
expression of MmaA4 strongly reversed the inhibition of keto-
mycolate synthesis observed with dioctylamine (Figure 4A).
Similarly, overexpression of CmaA2 reversed the accumulation
of unsaturated ketomycolates seen with dioctylamine treatment
(Figure 4B). Overexpression of MmaA2 and PcaA also reversed
the accumulation of unsaturated alpha mycolate in dioctyl-
amine-treated cells. InMmaA2-expressing cells, the predominant
alphamycolate thataccumulatedwas fully saturated (whitearrow-
head in Figure 4C), whereas in PcaA-expressing cells, the alpha
mycolate was mixture of monounsaturated and dicyclopropa-
nated lipids (Figure 4C). Although diunsaturated alpha mycolate
is the major lipid in dioctylamine-treated cells (black arrowhead
in Figure 4C), none of this lipidwas visible in the PcaAoverexpres-
sor. In contrast, although the lack of methoxymycolate in dioctyl-
amine-treated cells is consistent with loss of MmaA3 function,
overexpression of MmaA3 did not reverse this effect (Figure S3).
This suggests that MmaA3 may be an indirect target of dioctyl-
amine, possibly through other mycolic acid methyltransferases.
Dioctylamine Inhibits the Methyltransferase Activity
of CmaA2 In Vitro
To examine the in vitro activity of M. tuberculosis mycolic acid
methyltransferases and their inhibition of dioctylamine, we
developed a new enzymatic assay based on a colorimetric assay
that detects conversion of S-adenosylhomocysteine (SAH) to
homocysteine by SAH hydrolase (Lozada-Ramirez et al., 2006).
This assay is diagrammed in Figure S4. Using this assay, we
screened unsaturated fatty acids, including oleic, nervonic,
arachidonic, and cis-11,14-eicosadienoic acid as substrates of
M. tuberculosis CmaA2. Although none of these substrates are
close in structure to the authentic substrate (i.e., a long chain
acyl-ACP), we were able to demonstrate cyclopropanation of
double bonds and determine kinetic parameters using a Line-
weaver-Burk plot (Figure S5B). Of these, Eicosadienoic acid
(Km = 16.8 mM and kcat = 0.03 s
1) was the best candidate to
test the inhibitory effect of dioctylamine. An accurate IC50 was
not obtainable because we had to use a relatively large amount
of protein (4 mM) in order to observe the reaction progress.
However, the inhibition from dioctylamine was obvious as it
reduced the activity of CmaA2 in a concentration-dependent
manner (Figure S5A). When 2 mM dioctylamine was added to
the reaction, the rate was reduced by 50%, indicating a fairly
potent inhibition against the enzyme and consistency with dio-
ctylamine inhibition of the cyclopropane fatty acid synthase
from E. coli. These data demonstrate that dioctylamine is a direct
inhibitor of mycolic acid methyltransferases.
The Structure of CmaA2 with Bound Dioctylamine
Reveals the Molecular Basis for Activity
To further demonstrate that dioctylamine is a direct inhibitor of
mycolic acid methyltransfer and explore the molecular basis
for its activity, we solved the structure of the CmaA2 protein in
complex with the compound. The structure was solved by
molecular replacement at 2.67 A˚ resolution (Table 1). The overall
fold is largely similar to the previously reported structure ofLtd All rights reserved
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(Huang et al., 2002), showing an rmsd of 0.315 A˚ after superim-
position (Figure 5A). Moreover, the lipophilic ligands in the two
structures are similarly oriented in the binding site of the mycolic
acyl substrate. Like DDDMAB, dioctylamine adopts a U-shape
conformation with the nitrogen pointing to the previously
revealed SAM binding pocket and the two aliphatic chains
extending to the catalytic site entrance. Modeling SAM into the
active site by superimposing the MmaA4-SAM structure (PDB
code 2FK8) with CmaA2-SAH and dioctylamine complex, we
see the nitrogen of dioctylamine is approximately 3.1 A˚ away
from the active methyl group of SAM, indicating that the nitrogen
is situated at the position of the substrate double bond to be
modified. Whereas the hydrophobic binding pocket binds the
aliphatic chains of DDDMAB and dioctylamine similarly, the
ammoniumor amine nitrogens differ substantially in their interac-
tion with the protein (Figure 5B). For both of the species, the resi-
dues within 5 A˚ distance from nitrogen include Tyr24, Tyr41,
Gly145, Glu148, and Tyr247. Tyr41 stabilizes the ammonium of
Figure 4. Mycolic Acid Methyltransferases Are
Direct Targets of Dioctylamine
(A) Wild-type BCG-R (plus empty vector) or BCG-R
carrying a multicopy plasmid expressing MmaA4
(MmaA4 OE) were treated with vehicle (left lanes) or dio-
ctylamine (right lanes) and radiolabeled mycolic acids
were analyzed by TLC.
(B) Wild-type BCG-R (plus empty vector) (top panel) or
BCG-R carrying a multicopy plasmid expressing CmaA2
(CmaA2 OE) (bottom panel) were treated with dioctyl-
amine and radiolabeled mycolates were analyzed by
two-dimensional argentation TLC.
(C) Wild-type BCG-R (plus empty vector) (upper left) or
BCG-R carrying a multicopy plasmid expressing PcaA
(PcaA OE) (upper right) or MmaA2 (MmaA2 OE) (lower
left) were treated with dioctylamine and radiolabeled
mycolic acids were analyzed by two-dimensional argenta-
tion TLC. The black arrowhead indicates alpha mycolate
with two double bonds and the white arrowhead indicates
mature alpha mycolate with two cyclopropane rings.
DDDMAB through cation-p interaction. In
contrast, when dioctylamine binds to the same
site, its nitrogen drifts 0.5 A˚ away from the
face of Tyr41. Gly145 tilts toward the nitrogen
at the same time, with its backbone oxygen
forming a van der Waals interaction with the
nitrogen atom at a 3.2 A˚ distance. This distance
is 4.0 A˚ in the structure in complex with
DDDMAB, which is likely the result of the steric
repulsion from the two methyl groups of the
ammonium. Thus, this structural analysis of
the dioctylamine-CmaA2 interaction predicts
that amine-based inhibitors of these will be
more potent than ammonium-based inhibitors.
Dioctylamine Is a Growth Inhibitor of BCG
and M. tuberculosis
To test the hypothesis that simultaneous inhibi-
tion of multiple mycolic acid methyltransferases
is lethal to mycobacteria, we grew BCG-R and M. tuberculosis
Erdman in 7H9 media or 7H10 plates supplemented with
different concentrations of dioctylamine.We found thatM. tuber-
culosis growth was partially inhibited by 4 mM and completely
inhibited by a 6 mM (Figure 6A). Similar results were obtained
with M. tuberculosis grown on solid media containing dioctyl-
amine (Figure 6B) and with BCG-R in liquid and solid media
(data not shown). We did find that there was a considerable inoc-
ulum effect, and at higher inoculums the inhibitory effect was
seen at higher concentrations of dioctylamine (data not shown).
As the growth inhibitory concentration of dioctylamine is similar
to the concentration active against mycolic acid methyltrans-
ferases, this data, coupled with the genetic data presented
above, strongly suggest that mycolic acid modification may be
an essential function for slow growing mycobacteria.
To further substantiate that growth inhibition effect of dio-
ctylamine on mycobacteria is indeed related to its effect on
cyclopropanation, we used another tool compound, hexadecyl-
trimethylammonium bromide (CTAB). This compound, whichChemistry & Biology 16, 499–509, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 503
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lize in the active site of CmaA1 and shares an ammonium
head group similar to DDMABB, suggesting that it should be
a weaker inhibitor than dioctylamine if growth inhibition is attrib-
utable to binding to mycolic acid methyltransferases. Consistent
with this structure-activity prediction, we found CTAB to be
5-fold less active than dioctylamine in inhibiting mycobacterial
growth (Figure 6C). CTAB was also approximately 5-fold less
active than dioctylamine in inhibitingmethoxymycolate synthesis
in vivo (Figure 6D).
To further demonstrate that inhibition of growth by dioctyl-
amine is the direct result of inhibition of multiple mycolic acid
methyltransferases, we overexpressed these enzymes and
tested for resistance to dioctylamine. None of the strains over-
expressing a single enzyme (either MmaA1, MmaA2, MmaA3,
MmaA4, CmaA2, or PcaA) were resistant to dioctylamine (data
not shown), which is consistent with the nonessentiality of these
gene products in prior genetic experiments. We then overex-
pressed simultaneously, from a single plasmid, six different
enzymes of this family: MmaA1, MmaA2, MmaA3, MmaA4,
CmaA2, and PcaA. The strain overexpressing these six enzymes
(mgm1950) grew three times as fast as the control strain
(mgm1910) in 6.5 mM dioctylamine, indicating partial resistance
(Figures 6E and 6F). This data indicates that dioctylamine kills
M. tuberculosis by inhibiting multiple methyltransferases.
Mycolic Acid Modification Is Required for Acid Fastness
and Intrinsic Resistance to Antibiotics
The activity of dioctylamine against mycolic acid methyltrans-
ferases allowed us to probe the physiologic function of this
Table 1. Data Collection and Refinement Statistics for CmaA2 in
Complex with Dioctylamine
Data collection
Space group I4122
Unit cell dimensions (A˚) a = b = 106.86
c = 224.98
Molecules/asymmetric unit 1
Wavelength (A˚) 0.9795
Resolution (A˚) 502.68
Completeness (%) 99.7 (98.1)
No. of reflections 287,172
I/sI 20.1 (1.62)
Rsym 0.0413 (0.76)
Refinement statistics
Resolution (A˚2) 38.742.68
No. of reflection work 18,719
No. of protein atoms 2,380
No. of water molecules 41
No. of heteroatoms 21
Rcryst (%) 22.29
Rfree (%) 24.30
Rmsd bond lengths (A˚) 0.012
Rmsd angles (A˚) 1.157
Mean temperature factor (A˚2) 61.33504 Chemistry & Biology 16, 499–509, May 29, 2009 ª2009 Elsevierunique lipid modification in a way not possible using the previ-
ously isolated single gene mutants or, as in prior studies, using
overexpression of individual enzymes (Yuan et al., 1998). To
test whether cyclopropanation contributes to antibiotic resis-
tance, we tested sublethal concentrations of dioctylamine in
combination with sublethal concentrations of isoniazid (INH),
ciprofloxacin, and kanamycin.We found strong synergy between
dioctylamine and both INHandciprofloxacin (Figures 7A and7B),
but no synergy with kanamycin (data not shown). To show that
this synergy is related to increased drug penetration in dioctyl-
amine-treated cells, we measured the uptake of radiolabeled
ciprofloxacin in bacteria treated with 4 mM dioctylamine. We
found a significant increase in ciprofloxacin penetration into dio-
ctylamine-treated cells, an effect that was most evident after
5 min, but was sustained after 40 min (Figure 7C). These results
suggest that the mechanism of synergy between these two anti-
biotics facilitated uptake of ciprofloxacin by dioctylamine’s
effects on the mycobacterial membrane. A similar mechanism
may explain synergy between INH and dioctylamine, although it
is possible that the INH synergy is also a result of their combined
effect on mycolic acid synthesis.
Acid fastness of mycobacteria, a hallmark of this genus, is
thought to reflect the hydrophobicity and structure of mycolic
acids in the cell wall. This idea is supported by prior findings
that M. tuberculosis lacking kasB display both loss of acid fast-
ness and attenuation (Bhatt et al., 2007). We tested the effect
of 4 mM dioctylamine on the acid fastness of BCG-R and found
that most of the bacteria lost their acid fastness (Figure 7D),
despite only partial growth inhibition.
DISCUSSION
Cyclopropanation is a common membrane modification in
bacteria and plants (Bao et al., 2002; Grogan and Cronan,
1997). In most cases, the physiologic function of cyclopropana-
tion is poorly defined, although cyclopropanation clearly has
substantial effects on membrane fluidity in model systems
(McGarrity and Armstrong, 1981; Nagamachi et al., 1991). Path-
ogenic mycobacteria have an extensive set of cyclopropane
modifications that decorate the signature lipid of themycobacte-
rial cell wall, the mycolic acid. Recent studies have strongly
implicated mycolic acid cyclopropanation in M. tuberculosis
pathogenesis through its effect on the immunomodulatory prop-
erties of trehalose dimycolate (Rao et al., 2005, 2006). However,
these studies did not clearly establish mycolic acid methyltrans-
ferases as an attractive drug target. Here we demonstrate that
chemical inhibition of multiple mycolic acid methyltransferases
is lethal to mycobacteria and causes pleiotropic alterations in
cell envelope structure and drug susceptibility. These studies
provide strong scientific basis for targeting mycolic acid cyclo-
propanation as an antibiotic strategy against M. tuberculosis.
Our findings also reveal novel physiologic roles of cyclopropa-
nation in mycobacteria. Although some prior studies have indi-
cated a role for cyclopropanation in membrane fluidity and
permeability (George et al., 1995; Yuan et al., 1998), the exact
role of cyclopropanation in the physiology of pathogenic myco-
bacteria was unclear. A prior study indicated that the antituber-
cular thiacetazone may affect cyclopropanation, but this study
concluded that the growth inhibitory effect of this drug wasLtd All rights reserved
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This conclusion was based on the difference between the
minimum inhibitory concentration of thiacetazone and the
concentration required to affect cyclopropanation. In a more
recent paper, the authors show that MmaA4 is required for
activity of thiacetazone and that deletion ofmmaA4 confers resis-
tance, rather than hypersensitivity, to the drug (Alahari et al.,
2009). Using dioctylamine as a tool compound, we suggest that
pharmacologic inhibition of this enzyme class causes loss of
viability, a novel and unanticipated finding. Our finding that
mycolic acid methyltransferases are essential for viability
suggests an unanticipated role for mycolic acid modification in
some essential cellular process. The most likely cause of this
essentiality is lethal dysregulation of membrane fluidity leading
to impaired protein localization or cell division. Although an off-
target effect of dioctylamine causing cell death is possible, we
Figure 5. Structures of M. tuberculosis
CmaA2 in Complex with Dioctylamine and
DDDMAB/SAH
(A) The a-Carbon traces and ligands of the two
structures are shown with dioctylamine colored
pink and DDMAB/SAH colored green. The two
structures show similar overall folding. All the
ligands including bicarbonate are represented as
ball and stick. The surface of the protein is shown
with transparency. (B) Stereo diagram of the active
site residues in proximity to dioctylamine or
DDDMABnitrogens.Dioctylamine and thecognate
bicarbonate are represented as ball and stick,
while DDDMAB and the cognate bicarbonate are
represented as stick. The specific van der Waals
interaction between the backbone oxygen of
Gly145 and the nitrogen of dioctylamine is shown
as dotted line.
believe this is unlikely because: (1) cell
death is observed at the same concentra-
tion required to inhibit multiple methyl-
transferases in vivo; (2) overexpression
of multiple enzymes can partially reverse
the growth defect; (3) the structure of
CmaA2 protein with dioctylamine both
reveals that this enzyme is a direct target
and that dioctylaimine is acting as a
substrate mimic rather than a general
SAM antagonist. This makes nonspecific
inhibition of other SAM-dependent meth-
yltransferases (such as DNAmethyltrans-
ferases) with nonlipid substrates unlikely.
The essential physiologic role of mycolic
acid methyltransferases is an area of
interest that will be the subject of future
investigations.
Although dioctylamine is unlikely to be
a useful antimicrobial due to host toxicity
(data not shown), our data provide strong
support for targetingmycolic acidmethyl-
transferases for inhibitor development
and provides a structural framework for
optimizing active site binding through structure guided design.
The structures of CmaA2 reveal different binding determinants
for ammonium or amine-based inhibitors. The ammonium ion
mimics the carbocation intermediate of the cyclopropanation
reaction and is stabilized by cation-p interaction. In contrast,
throughmimicking an electron-donating double bond, the amine
nitrogen atom of dioctylamine forms a van der Waals interaction
with Gly145. This interaction will not occur in a mycolate sub-
strate and provides a structural explanation for the successful
competitionof dioctylaminewith thenaturalmycolate substrates.
Moreover, this interaction may contribute more than cation-p
interaction to enhancing inhibitor binding, evident from our
finding that acylamine compounds are more potent than ammo-
nium compounds (CTAB) at inhibiting cyclopropanation. This
indicates that amine-based inhibitors may serve as a template
for further drug development.Chemistry & Biology 16, 499–509, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 505
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M. tuberculosis
(A) M. tuberculosis Erdman was grown in 7H9
media, supplemented with 0 (vehicle)(C), 2 (-), 4
(:), and 6 mM (;) dioctylamine. OD600 measure-
ments were taken daily. A representative experi-
ment out of five is shown.
(B) M. tuberculosis Erdman was grown on 7H10
plates, impregnated with 0, 4, or 10 mM dioctyl-
amine. The plates were kept at 37C with 5%
CO2 for 4 weeks.
(C) BCG-R was grown in the indicated concentra-
tions of CTAB and bacterial growth was measured
by OD.
(D) Radiolabeled mycolic acids from BCG-R
treated with the indicated concentrations of CTAB
(mM) were separated by one-dimensional TLC.
(E) BCG-R overexpressing six methyltransferases
(MmaA1-4, PcaA, and CmaA2) (MGM1950) is
more resistant to dioctylamine than BCG-R with
vector alone (MGM1910). A representative exper-
iment out of four is shown.
(F) The ratio of growth in the presence of dioctyl-
amine to without dioctylamine at the 192 hr time
point from the experiment in (E).SIGNIFICANCE
The prevailing model of rational antimicrobial development
envisions a one-to-one relationship between target and
inhibitor (Mdluli and Spigelman, 2006; Payne et al., 2007).
Inhibitors are optimized for specificity for a single protein
target, rather than a group of protein targets. The disadvan-
tage of this strategy is that mutation in a single target arises
easily, generating drug resistance, as has been observed
with many antimicrobials, including antimycobacterials.506 Chemistry & Biology 16, 499–509, May 29, 2009 ª2009 ElsevieThe findings presented here introduce a variation on the
inhibitor-target relationship by demonstrating that multiple
members of a highly conserved enzyme class can be simul-
taneously targeted by a single compound, thereby achieving
physiologic effects not possible with inhibition of any single
member of the enzyme group. As such, we propose that
the mycolic acid methyltransferases may be an Achilles
heel of themycobacterial cell wall as their conserved protein
structure but diverse biosynthetic functions allows a single
inhibitor to have pleiotropic effects on the organism. InFigure 7. Mycolic Acid Methyltransferases
Are Required for Drug Resistance and Acid
Fastness of Mycobacteria
(A) BCG-R was treated with INH, dioctylamine
(Dio), or both at the indicated concentrations and
growth was measured by OD at 600 nm.
(B) BCG-R was treated with ciprofloxacin (Cipro),
dioctylamine (Dio), or both at the indicated
concentrations and growth was measured by OD
at 600 nm.
(C) Accumulation of 14C ciprofloxacin in untreated
(white bar) or dioctylamine treated (4 mM; black
bar) at the indicated time points after 14C cipro-
floxacin addition. The y axis is counts per minute.
(D) Untreated or dioctylamine (4mM)-treated cells
were examined by acid fast staining using the
modified Kinyoun technique.r Ltd All rights reserved
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et al., 2009) indicate that targetingmultiple enzymes simulta-
neously is feasible and we speculate that this strategy may
delay the emergence of resistance to a mycolic acid methyl-
transferase inhibitor as mutation of multiple enzymes would
be required. Rather than seeking a clinically useful inhibitor
that specifically targets one enzyme in the class, we would
seek an inhibitor with broad activity against mycolic acid
methyltransferases with the goal of mimicking the effects
observed in this study, not least of which are cell death
and the enhancement of activity of other established antimy-
cobacterials through facilitated drug penetration.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions
M. smegmatis mc2155 was grown in 7H9 liquid media supplemented with
0.05% Tween 80, 0.5% glycerol, and 0.5% dextrose. BCG-R (kindly provided
by M. Behr), BCG-P, and M. tuberculosis Erdman were grown in 7H9 media
supplemented with 0.05% Tween 80, 0.5% glycerol, and 10% OADC (for
M. tuberculosis) or ADS (for BCG). Growth on plates was done on 7H10 plates
supplemented with glycerol and OADC or ADS at the same concentrations.
Growth in 7H9 media was monitored by optical density (OD) at 600 nM
measurement. Antibiotic concentrations were 20 mg/ml for kanamycin,
50 mg/ml for hygromycin, and 12.5 mg/ml for zeocin.
Construction of Mutant Strains
Deletion of mmaA1 and cmaA2 was done as described previously (Glickman
et al., 2001; Makinoshima and Glickman, 2005). Briefly, a temperature-sensi-
tive mycobacteriophage (phAE87) was used to introduce a hygromycin-resis-
tance cassette interrupting the candidate gene at 39C. The bacteria were
plated on 7H10 plates with hygromycin. The resulting colonies were analyzed
by southern blotting using a probe flanking the gene of interest. Removal of
mmaA3 previously introduced via the attB site on the pMV306kan plasmid
(marker exchange) was done be electroporating a pMV306zeo (pMV306kan
with a zeocin-R cassette replacing the kanamycin-R) and plating the bacteria
on plates supplemented with zeocin.
Mycolic Acid Preparation and Analysis
Mycobacteria were grown in 7H9 media to an OD600 of 0.3–0.5 in a volume of
50–200 ml. 14C-labeled acetic acid was added to the media at a concentration
of 1 mCi/ml, and the bacteria were allowed to grow for 6 hr (in the presence of
dioctylamine) or 24 hr (without dioctylamine) more. The bacteria were har-
vested, and mycolic acids were extracted as previously described (Glickman
et al., 2001). Single dimension separation of mycolic acid classes was done on
a normal phase silica gel HPTLC plate (Analtech) and run in a 95:5 mixture of
hexanes/ethyl acetate for five to six developments. Two-dimensional separa-
tion was done by immersing 90% of the TLC plate in 10% silver nitrate, acti-
vating at 130C for 20 min, running the sample along the line with no silver
nitrate (first dimension), rotating the TLC plate 90, and running for five to six
additional developments into the silver nitrate impregnated area. After comple-
tion, autoradiograms were developed using a Kodak BioMax Transcreen LE
intensifying screen at 80C. NMR analysis was done as previously described
(Glickman et al., 2001). Bacteria were grown to an OD600 of 0.8, in a volume of
400–500 ml. Bacteria were harvested and mycolic acids were prepared as
before and resuspended in d-chloroform for the NMR analysis.
Dioctylamine and CTAB Preparation and Use
Dioctylamine was purchased from Sigma-Aldrich. One hundred microliters
was diluted in 400 ml of DMSO and the volume was complemented with
33 ml of 100% ethanol to produce a stock solution in final concentration of
10 mM. The vehicle solution of DMSO and ethanol alone was used as control.
CTAB was purchased from Sigma-Aldrich and a stock solution of 10 mM in
water was prepared.Chemistry & Biology 16Radiolabeled Ciprofloxacin Permeability
14C-ciproflixacin (15 mCi/mmol) was purchased from Moravek biochemicals.
Permeability testing was done as described previously (Chevalier et al.,
2000; Liu et al., 1996). Fifty milliliters total volume of BCG-R was grown with
or without 4 mM dioctylamine to an OD600 of 0.5. The cells were concentrated
and resuspended in 1ml to 1.53 1010 cfu/ml and left to rotate at 8 rpm at 37C
for 45 min. Carbonyl cyanide 3-chlorophenyl hydrazone (Sigma-Aldrich) was
added to a final concentration of 0.1 mM for 30 min, 14C-ciprofloxacin was
added to a concentration of 25 mM, and cells were left rotating at 37C.
Samples of 200 ml were removed at 5, 20, and 40 min. Each sample was
washed five times with PBS, filtered through a 0.45 mm GF/C filter on a Unifil-
ter-96 plate (Perkin-Elmer), washed again, and left to dry overnight. Radioac-
tivity was measured by scintillation reader (Packard).
Production of M. tuberculosis CmaA2
Cloning, protein expression, and purification of CmaA2 were performed simi-
larly as previously reported (Huang et al., 2002), except that amodified pET28b
vector was used to incorporate TEV cleavage sequence right ahead of the
N terminus of the protein. The protease TEVwas consequently used to remove
the His6 tag.
Crystallization and Data Collection
2mgmL1 CmaA2 in 25 mM Tris-HCl (pH 8.0) was incubated in ice with 50 mM
dioctylamine for 20min. The protein was then concentrated to 10mgmL1 and
crystallized at 18C by hanging drop vapor diffusion. Each drop contained an
equal volume of the protein solution and reservoir solution (2 M ammonium
sulfate and 0.1 M CAPS [pH 9.0]). The crystal of binary CmaA2 was flash-
frozen in liquid nitrogen using cryoprotectant paratone. The diffraction data
were collected at beamline 19-ID at the Advanced Photon Source, Argonne
National Laboratory, and then was processed and reduced using HKL2000
(Otwinowski and Minor, 1997).
Structure Determination and Model Refinement
The structure of CmaA2 was solved by molecular replacement using Molrep
(Vagin and Teplyakov, 1997) in CCP4. CmaA2-SAH-DDDMAB (PDB code
1KPI) with all nonprotein molecules removed, was used as the search model.
The crystal was in a space group of I422. There was one protein molecule in
each unit cell with dimensions of a = b = 106.86 A˚, c = 224.98 A˚, and a = b =
g = 90. A single solution for the molecular replacement was obtained. After
rigid-body and restrain refinement by Refmac5 (Murshudov et al., 1997) in
CCP4, the Rcryst and Rfree were 24.6% and 26.8%, respectively. These values
were reduced to 23.5% and 26.0% once dioctylamine and bicarbonate ion
were manually built in the model by examining the Fo  Fc map in XtalView
(McRee, 1999). The final model containing residues 9–302 as well as 41 water
molecules was obtained after further cycles of model building and PHENIX
(Zwart et al., 2008) refinement yielding R factors of 22.3% and 24.3%. The
full crystallization statistics are given in Table 1.
Enzymatic Assay for CmaA2
All assays were performed in the presence of a 100 mM (pH 7.5) phosphate
buffer. Twenty-five micromoles of SahH, 250 mM NAD, and unsaturated fatty
acid were preequilibrated for more than 5min. After 400 mMDTNBwas added,
the solution was blanked and added to preincubated 4 mM CmaA2/100 mM
SAM to start the reaction. To examine the inhibition by dioctylamine, the dio-
ctylamine/DMSO solution was added together with DTNB to the reaction
mixture containing 20 mM cis-11,14-eicosadienoic acid.
ACCESSION NUMBERS
The structure of CmaA2 in complex with dioctylamine has been deposited in
Protein Data Bank with accession code 3HEM.
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